Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety of in Vivo- CAR-T Cell Immunotherapy Targeting CD19/CD20 for the Treatment of Relapsed/Refractory B-cell Lymphoma

NCT07775508 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT07775508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07775508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety of in Vivo- CAR-T Cell Immunotherapy Targeting CD19/CD20 for the Treatment of Relapsed/Refractory B-cell Lymphoma
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2026
Completion date
January 1, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma